Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mastocytosis, Systemic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Burkitt Lymphoma 1Breast Neoplasms 1Breast Carcinoma In Situ 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Specimen Handling 8Tamoxifen 6Standard of Care 4Practice Guidelines as Topic 4Radiotherapy 3Methods 3Sentinel Lymph Node Biopsy 2Radiation Dose Hypofractionation 2Radiation 2Educational Status 2Early Intervention, Educational 2Counseling 2ruxolitinib 1pembrolizumab 1exemestane 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1abemaciclib 1Watchful Waiting 1Telemedicine 1Taxes 1Tablets 1Surveys and Questionnaires 1Starch 1Reverse Transcriptase Polymerase Chain Reaction 1Ranitidine 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Carcinoma In Situ × Ranitidine × 1 year × Clear all
NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

Phase 2/3 Completed
130 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡